CLINICAL TRIALS AND OBSERVATIONS Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
نویسندگان
چکیده
1University College London, London, United Kingdom; 2Rambam Medical Center and Technicon, Israel Institute of Technology, Haifa, Israel; 3Clinical Trial Service Unit, Oxford, United Kingdom; 4Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom; 5Bristol Haematology and Oncology Centre, Bristol, United Kingdom; 6Nottingham University, Nottingham, United Kingdom; 7Mayo Clinic College of Medicine, Rochester, MN; 8Ireland Cancer Center, University Hospitals of Cleveland, OH; 9Imperial College London, London, United Kingdom; 10University of Glasgow, National Blood Transfusion Service, Glasgow, United Kingdom; 11Abramson Cancer Center, University of Pennsylvania, Philadelphia; 12Montefiore Medical Center North Division and New York Medical College, Bronx; 13Northwestern University Feinberg School of Medicine, Chicago, IL; and 14University College London Hospitals, London, United Kingdom
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
Patel, Elisabeth Paietta, Martin S. Tallman and Anthony H. Goldstone Hillard Lazarus, Selina M. Luger, David I. Marks, Andrew K. McMillan, Anthony V. Moorman, Bella Adele K. Fielding, Jacob M. Rowe, Georgina Buck, Letizia Foroni, Gareth Gerrard, Mark R. Litzow, lymphoblastic leukemia regimen enhances long-term outcomes in Philadelphia positive acute UKALLXII/ECOG2993: addition of imatinib to a ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Imatinib mesylate, an inhibitor of the BcrAbl tyrosine kinase, has modest activity in refractory/relapsed Philadelphia chromosome (Ph)–positive acute lymphocytic leukemia (ALL). Use of concurrent chemotherapy and imatinib mesylate in newly diagnosed Ph-positive ALL was explored. There were 20 patients who received hyper–CVAD (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and ima...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)
In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph ALL patients received imatinib upon detection of MRD after SCT. Bcr-a...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)
The best strategy for incorporating imatinib in front-line treatment of Ph acute lymphoblastic leukemia (ALL) has not been established. We enrolled 92 patients with newly diagnosed Ph ALL in a prospective, multicenter study to investigate sequentially 2 treatment schedules with imatinib administered concurrent to or alternating with a uniform induction and consolidation regimen. Coadministratio...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis
The BCR-ABL fusion, the molecular equivalent of the Philadelphia translocation, gains importance for treatment stratification in adult acute lymphoblastic leukemia (ALL). In this prospective study, samples from 478 patients with CD101 B-cell precursor ALL (c-ALL and pre-B ALL) underwent BCR-ABLreversetranscription–polymerase chain reaction (RT-PCR) analysis with double testing of positive sampl...
متن کامل